IL-10 in Mycobacterial Infection
Infection by Mycobacterium leprae elicits a spectrum of clinical presentations.1 Because these clinical manifestations correlated with the level of cell-mediated immunity (CMI) to the pathogen, leprosy serves as a useful model to study human immune responses to infection. At one pole, tuberculoid patients are able to restrict growth of the pathogen as demonstrated by the presence of relatively few skin lesions containing few bacilli. These patients have strong CMI to the pathogen as evidenced by vigorous T-cell responses in vitro and skin test reactivity to challenge with M. leprae. At the opposite pole, lepromatous patients have disseminated disease as manifested by numerous skin lesions containing large numbers of bacilli. The T cells of these patients are specifically unresponsive to M. leprae although they produce significant quantities of antibodies against M. leprae antigens.
KeywordsPleural Fluid Cutaneous Leishmaniasis Mycobacterial Infection Lepromatous Leprosy Skin Test Reactivity
Unable to display preview. Download preview PDF.
- 1.Ridley DS, Jopling WH. Classification of leprosy according to immunity A five-group system. Int J Lepr 1966; 34: 255–273.Google Scholar
- 2.Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Amer Rev Tuberc 1955; 71: 616–634.Google Scholar
- 24.Sieling PA, Wang X-H, Gately MK et al. IL-12 regulates T helper Type 1 cytokine responses in human infectious disease. 1993, J Immunol. in press..Google Scholar
- 33.Meunier L, Gonzalez-Ramos A, Cooper KD. Heterogeneous populations of class II MHC’ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J Immunol 1993; 151: 4067–4080.PubMedGoogle Scholar
- 35.de Waal-Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibilty complex expression. J Exp Med 1991; 174: 915–924.PubMedCrossRefGoogle Scholar